Colorado Becomes First State to Cap Price of Rx Enbrel

The Colorado Prescription Drug Affordability Board has set an upper payment limit on the prescription drug Enbrel, which is used to treat rheumatoid arthritis and other autoimmune conditions, reports Colorado Newsline. This change caps insurer and patient annual payments at approximately $31,000, a decrease from the 2023 average cost of $53,049. Supporters say this is a landmark step toward reducing high-cost prescription burdens for patients. The cap is scheduled to take effect in 2027. Some stakeholders caution that while the price reduction addresses one affordability barrier, it does not directly solve broader issues like access, insurance benefit design, and the complex cost dynamics of drug markets.